Haemonetics Corporation (HAE) is currently Undervalued by 38.80%

Haemonetics Corporation (HAE) appears undervalued by approximately 38.80% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Upside (live) 38.80% (from live valuation API)
Confidence (live) 8/10 (High)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$74.88

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Haemonetics Corporation overvalued or undervalued?

Intrinsic value work anchors Haemonetics Corporation on owner earnings and balance-sheet capacity; the current quote trades above that anchor, which frames the stock as relatively rich on a fundamentals-first view.

Versus historical valuation bands, HAE is closer to the upper end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.

Forward market expectations are elevated: the price requires heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.

Key metrics

P/E ratio: 27.4x
Revenue growth (TTM y/y): 4%
Profit margin: 30.5%
Fair value (model): Unlock

Next steps

Frequently asked questions — HAE

Is HAE overvalued right now?

A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for HAE, then validate with fundamentals and peer multiples.

What is Haemonetics Corporation's intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether HAE trades above or below fair value. At $74.88, Haemonetics Corporation currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Haemonetics Corporation's intrinsic value calculated?

Tickerplace calculates HAE's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is HAE undervalued right now?

Based on our 2026 valuation models, Haemonetics Corporation (HAE) appears undervalued at $74.88 with about 38.8% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.

Peers for HAE: open their overvalued / undervalued view.

Instant valuation answer